US Patent

US11117871 — Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof

Method of Use · Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2038-03-13 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms CS1 and CS9 of the compound GSK1278863, a hypoxia-inducible factor prolyl hydroxylase inhibitor.

USPTO Abstract

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Drugs covered by this patent

Jesduvroq (DAPRODUSTAT) · GSK

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq

Patent Metadata

Patent number: US11117871
Jurisdiction: US
Classification: Method of Use
Expires: 2038-03-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: GlaxoSmithKline Intellectual Property No 2 Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.